secwatch.observer — SEC 8-K summary
======================================

Issuer:     Peak Bio, Inc. (—)
CIK:        0001834645
Form:       8-K
Filed at:   2023-01-09T23:59:59+00:00
Accession:  0001193125-23-004066
Event type: regulatory
Sentiment:  negative
Materiality: 0.90
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Peak Bio receives Nasdaq delisting determination; suspension effective Jan 10, 2023
--------------------------------------------------------------------------------

- Nasdaq Panel issued delisting letter Jan 6, 2023, after Dec 8 hearing to appeal prior deficiency notice.
- Failure to meet minimum 1,000,000 unrestricted publicly held shares (Listing Rule 5505(a)(2)).
- Warrants also delisted because underlying common stock does not qualify for initial listing.
- Trading suspended at open Jan 10, 2023; securities expected to move to OTC Pink Market.
- Company had previously disclosed Nov 1, 2022 notice; hearing stayed suspension pending Panel decision.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1834645/000119312523004066/0001193125-23-004066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1834645/000119312523004066/d447598d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-004066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer